Belite Bio (BLTE)

• Market cap: $3.81B
• 1 day: -9.3%
• 5 days: -0.46%
• 1 month: 20.81%
• 3 months: 72.15%
• 6 months: 68.46%
• Year to date: 68.59%
• 1 year: 32.29%
• 5 years: 930.97%
• 10 years: 930.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Employees: 25